Deciphera Pharmaceuticals, Inc.

NasdaqGS:DCPH Aktierapport

Börsvärde: US$2.2b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Deciphera Pharmaceuticals Förvaltning

Förvaltning kriterier kontrolleras 3/4

Deciphera Pharmaceuticals VD är Steve Hoerter, utsedd i Mar 2019, har en mandatperiod på 5.25 år. totala årliga ersättningen är $ 6.01M, bestående av 12.3% lön 87.7% bonusar, inklusive företagsaktier och optioner. äger direkt 0.084% av företagets aktier, värda $ 1.86M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 4.3 år respektive 9 år.

Viktig information

Steve Hoerter

Verkställande direktör

US$6.0m

Total ersättning

VD-lön i procent12.28%
Anställning som VD5.3yrs
Ägande av VD0.08%
Ledningens genomsnittliga anställningstid4.3yrs
Styrelsens genomsnittliga mandatperiod9yrs

Senaste uppdateringar av ledningen

Recent updates

Analysartikel • Apr 30

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Deciphera Pharmaceuticals, Inc. ( NASDAQ:DCPH ) shares have continued their recent momentum with a 61% gain in the last...
Seeking Alpha • Apr 26

Diving Into Deciphera Pharmaceuticals

Summary Shares of Deciphera Pharmaceuticals, Inc. have rallied 40% since October after positive trial data for vimseltinib in the treatment of TGCT. Vimseltinib is expected to make significant progress in the TGCT indication, as the only approved therapy is under a Risk Evaluation and Mitigation Strategy protocol. Deciphera's switch-control kinase inhibitor platform aims to produce compounds that target specific regions of kinases, resulting in higher activity and lower toxicity compared to current kinase inhibitors. An investment analysis around Deciphera Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking Alpha
Analysartikel • Mar 13

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysartikel • Dec 02

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysartikel • Sep 25

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Key Insights Deciphera Pharmaceuticals' estimated fair value is US$21.93 based on 2 Stage Free Cash Flow to Equity...
Analysartikel • Jul 26

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysartikel • Jun 22

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Key Insights Deciphera Pharmaceuticals' estimated fair value is US$16.23 based on 2 Stage Free Cash Flow to Equity...
Analysartikel • May 08

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

Deciphera Pharmaceuticals, Inc.'s ( NASDAQ:DCPH ) price-to-sales (or "P/S") ratio of 7.7x might make it look like a buy...
Analysartikel • Apr 10

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysartikel • Dec 29

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 29

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Deciphera Pharmaceuticals (NASDAQ:DCPH) has been initiated as a buy at Cowen based on growth in sales of its advanced gastrointestinal stromal tumor treatment Qinlock (ripretinib) and its pipeline. The firm has a $25 price target (~68% upside based on Friday's close). Analyst Tyler Van Buren said that Decipera (DCPH) pipeline is "poised to break out" and a significant catalyst could come next month at the European Society for Medical Oncology (ESMO) annual meeting with data on vimseltinib and DCC-3116. Vimseltinib is in phase 1/2 for tenosynovial giant cell tumor, while DCC-3116 is in phase 1 for RAS/RAF mutant cancers in combination with Mekinist (trametinib). He added he sees peak sales of both candidates at a combined ~$1.3B. Seeking Alpha's Quant Rating view Deciphera as a buy with high marks for momentum, growth, and revisions.
Seeking Alpha • Aug 03

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Deciphera Pharmaceuticals (NASDAQ:DCPH) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.67 (vs. -$1.21 last year) and the consensus Revenue Estimate is $30.11M (+27.7% Y/Y). Over the last 3 months, EPS estimates have seen 4 upward revisions and 3 downward. Revenue estimates have seen 5 upward revisions and 3 downward.
Analysartikel • Jul 29

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Feb 11

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Deciphera's ripretinib failed a critical trial. The stock has been decimated. Although the company is struggling to make a comeback, it will take time.
Seeking Alpha • Nov 22

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Deciphera Pharmaceuticals is the unusual case of a commercial-stage company whose drug succeeds at first but then has a major setback. Top-line data from a key phase 3 trial suggest that their flagship drug will not be moving from later-line to second-line therapy for GIST. With buoying expenses, Deciphera needs to make a splash to increase revenues quickly, or else dilution is a serious risk. Though risky overall, Deciphera at these levels presents a very interesting risk/benefit case.
Analysartikel • Aug 26

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysartikel • May 10

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analys av ersättningar till VD

Hur har Steve Hoerter:s ersättning förändrats jämfört med Deciphera Pharmaceuticals:s resultat?
DatumTotal ersättningLönFöretagets resultat
Mar 31 2024n/an/a

-US$190m

Dec 31 2023US$6mUS$738k

-US$195m

Sep 30 2023n/an/a

-US$194m

Jun 30 2023n/an/a

-US$187m

Mar 31 2023n/an/a

-US$182m

Dec 31 2022US$4mUS$703k

-US$179m

Sep 30 2022n/an/a

-US$221m

Jun 30 2022n/an/a

-US$258m

Mar 31 2022n/an/a

-US$286m

Dec 31 2021US$9mUS$676k

-US$300m

Sep 30 2021n/an/a

-US$274m

Jun 30 2021n/an/a

-US$258m

Mar 31 2021n/an/a

-US$255m

Dec 31 2020US$8mUS$650k

-US$266m

Sep 30 2020n/an/a

-US$271m

Jun 30 2020n/an/a

-US$263m

Mar 31 2020n/an/a

-US$218m

Dec 31 2019US$9mUS$435k

-US$192m

Sep 30 2019n/an/a

-US$157m

Jun 30 2019n/an/a

-US$126m

Mar 31 2019n/an/a

-US$126m

Dec 31 2018US$447kn/a

-US$100m

Ersättning vs marknad: Steve s total kompensation ($USD 6.01M ) är ungefär genomsnittet för företag av liknande storlek på US marknaden ($USD 5.45M ).

Ersättning vs inkomst: Ersättningen för Steve har ökat samtidigt som företaget är olönsamt.

VD OCH KONCERNCHEF

Steve Hoerter (53 yo)

5.3yrs
Anställning
US$6,010,712
Kompensation

Mr. Steven L. Hoerter, also known as Steve, serves as Director at ORIC Pharmaceuticals, Inc. since August 2021. He has been President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since Ma...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Steven Hoerter
President5.3yrsUS$6.01m0.084%
$ 1.9m
Thomas Kelly
Executive VP9.3yrsUS$2.03m0.049%
$ 1.1m
Dashyant Dhanak
Executive VP & Chief Scientific Officerless than a yearUS$3.06m0%
$ 0
Daniel Martin
Senior VP & Chief Commercial Officer5.8yrsUS$1.58m0.036%
$ 801.7k
Matthew Sherman
Executive VP & Chief Medical Officer4.7yrsUS$2.13m0.084%
$ 1.8m
Kevin Brodbeck
Senior VP & Chief Technical Officerless than a yearinga uppgifteringa uppgifter
Jennifer Larson
Senior Vice President of Finance & Investor Relationsno datainga uppgifteringa uppgifter
Jeffrey Held
Senior VP & General Counsel5.3yrsinga uppgifteringa uppgifter
Lisa Price
Senior VP & Chief Human Resources Officer2.4yrsinga uppgifteringa uppgifter
Jama Pitman
Senior VP & Chief Development Officer4.3yrsinga uppgifter0.040%
$ 876.3k
Margarida Duarte
Senior VP & Head of International3.3yrsinga uppgifteringa uppgifter
Rodrigo Soto
Senior Vice President of Clinical Development3.4yrsinga uppgifteringa uppgifter
4.3yrs
Genomsnittlig anställningstid
53yo
Genomsnittlig ålder

Erfaren ledning: DCPH s ledningsgrupp anses vara erfaren ( 4.3 års genomsnittlig anställningstid).

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Steven Hoerter
President6.1yrsUS$6.01m0.084%
$ 1.9m
John Martin
Independent Director9.3yrsUS$388.59k0%
$ 0
Edward Benz
Independent Director7.7yrsUS$396.09k0%
$ 0
Patricia L. Allen
Independent Director7.8yrsUS$398.55k0%
$ 0
Ron Squarer
Independent Chairman4.5yrsUS$403.30k0%
$ 0
Jean-Yves Blay
Member of Scientific Advisory Board9yrsinga uppgifteringa uppgifter
James Bristol
Independent Director16.8yrsUS$414.77k0%
$ 0
John Condeelis
Member of Scientific Advisory Boardno datainga uppgifteringa uppgifter
Filip Janku
Member of Scientific Advisory Board9yrsinga uppgifteringa uppgifter
F. Hodi
Member of Scientific Advisory Board9yrsinga uppgifteringa uppgifter
Dennis Walsh
Independent Director9.3yrsUS$386.05k0.013%
$ 281.5k
John de Groot
Member of Scientific Advisory Boardno datainga uppgifteringa uppgifter
9.0yrs
Genomsnittlig anställningstid
62yo
Genomsnittlig ålder

Erfaren styrelse: DCPH s styrelse anses vara erfaren ( 9 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2024/06/11 15:56
Aktiekurs vid dagens slut2024/06/11 00:00
Intäkter2024/03/31
Årlig intjäning2023/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Deciphera Pharmaceuticals, Inc. bevakas av 15 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Madhu KumarB. Riley Securities, Inc.
Arlinda LeeCanaccord Genuity
Charles DuncanCantor Fitzgerald & Co.